Cellebrite DI (NASDAQ:CLBT - Free Report) had its price objective lifted by Needham & Company LLC from $17.00 to $21.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.
A number of other analysts have also recently commented on the company. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $14.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Lake Street Capital boosted their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. TD Cowen upped their price target on Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Finally, Craig Hallum increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $20.29.
Read Our Latest Report on Cellebrite DI
Cellebrite DI Stock Performance
NASDAQ CLBT traded down $0.28 on Thursday, hitting $18.81. The stock had a trading volume of 978,312 shares, compared to its average volume of 1,143,167. The firm has a 50-day moving average of $17.55 and a 200-day moving average of $14.20. Cellebrite DI has a 52-week low of $7.22 and a 52-week high of $21.00. The company has a market capitalization of $3.87 billion, a price-to-earnings ratio of -12.23, a price-to-earnings-growth ratio of 2.55 and a beta of 1.50.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The company's revenue was up 24.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 EPS. As a group, research analysts anticipate that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.
Institutional Trading of Cellebrite DI
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after buying an additional 1,017 shares during the last quarter. Tower View Wealth Management LLC boosted its stake in shares of Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company's stock worth $2,200,000 after acquiring an additional 1,500 shares in the last quarter. Venturi Wealth Management LLC increased its stake in shares of Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after acquiring an additional 2,000 shares during the last quarter. Meritage Portfolio Management boosted its stake in shares of Cellebrite DI by 12.0% in the third quarter. Meritage Portfolio Management now owns 27,831 shares of the company's stock valued at $469,000 after purchasing an additional 2,973 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in Cellebrite DI by 8.3% in the third quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company's stock valued at $861,000 after acquiring an additional 3,912 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
